Track the latest insights on levetiracetam price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.
Get real-time access to monthly/quaterly/yearly prices, Request Sample
During the second quarter of 2025, levetiracetam prices in the USA reached 36,500 USD/MT in June. Levetiracetam prices in the United States remained largely stable during the second quarter of 2025, supported by consistent demand from hospitals, clinics, and outpatient neurology practices. Mild fluctuations were observed due to variable costs of pharmaceutical-grade raw materials and rising energy expenses. Regulatory compliance and quality assurance requirements contributed to overall production costs. Despite occasional logistical bottlenecks, the supply chain remained mostly undisrupted. Market sentiment stayed firm, with levetiracetam prices aligning closely with input costs and stable therapeutic demand, particularly in the treatment of epilepsy and seizure-related disorders.
During the second quarter of 2025, levetiracetam prices in China reached 26,670 USD/MT in June. Levetiracetam prices in China exhibited mild fluctuations, primarily influenced by variable costs of active pharmaceutical ingredients and rising energy prices. Domestic production remained stable, supported by strong local manufacturing infrastructure and consistent demand from hospitals and neurology clinics. However, occasional supply chain disruptions and stricter regulatory controls contributed to modest price volatility. Export conditions and currency fluctuations also played a role in shaping cost dynamics. Despite these pressures, overall market sentiment remained stable, with prices closely aligned to input cost trends and steady therapeutic utilization.
During the second quarter of 2025, levetiracetam prices in India reached 34,118 USD/MT in June. Levetiracetam prices in India remained relatively stable throughout, supported by a strong domestic production base and consistent demand in both the public and private healthcare sectors. Input cost fluctuations, especially for raw materials and energy, introduced minor pricing variability. Regulatory compliance and quality standards added to production overheads, while exports experienced modest logistical delays. Despite these factors, the pricing environment reflected a well-balanced market, with manufacturers adjusting prices in line with material costs and maintaining a steady supply to meet therapeutic demand.
During the second quarter of 2025, levetiracetam prices in Germany reached 42,560 USD/MT in June. Levetiracetam prices showed moderate fluctuations, primarily influenced by variable energy tariffs and compliance-related production expenses. Demand from hospitals and clinics remained consistent, backed by levetiracetam’s established use in epilepsy treatment. While the domestic supply chain remained resilient, import dynamics and currency fluctuations had a slight impact on procurement costs. Environmental and pharmaceutical regulations continued to impact manufacturing margins. Overall, pricing remained firm, with adjustments reflecting changes in input costs and steady clinical utilization.
During the second quarter of 2025, levetiracetam prices in France reached 44,800 USD/MT in June. Levetiracetam prices in France remained largely stable, with slight variations attributed to changes in energy and operational costs. The country’s national health system ensured consistent demand, particularly in neurology departments. Local manufacturers maintained a reliable supply, though minor delays in raw material sourcing introduced temporary pressures. Regulatory obligations related to packaging, safety, and sustainability added to production expenses. Despite these factors, the market-maintained equilibrium, with prices generally aligned to supply chain conditions and steady prescription volumes.
The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing the Levetiracetam prices.
The report offers a holistic view of the global Levetiracetam pricing trends in the form of Levetiracetam price charts, reflecting the worldwide interplay of supply-demand balances, international trade policies, and overarching economic factors that shape the market on a macro level. This comprehensive analysis not only highlights current price levels but also provides insights into historical price of Levetiracetam, enabling stakeholders to understand past fluctuations and their underlying causes. The report also delves into price forecast models, projecting future price movements based on a variety of indicators such as expected changes in supply chain dynamics, anticipated policy shifts, and emerging market trends. By examining these factors, the report equips industry participants with the necessary tools to make informed strategic decisions, manage risks, and capitalize on market opportunities. Furthermore, it includes a detailed Levetiracetam demand analysis, breaking down regional variations and identifying key drivers specific to each geographic market, thus offering a nuanced understanding of the global pricing landscape.
Q2 2025:
In Europe, levetiracetam prices showed mild fluctuations, primarily influenced by varying energy and production costs across the region. Demand remained steady from both public healthcare systems and private providers, driven by its established role in epilepsy management. Countries such as Germany, France, and Italy maintained consistent usage, while their supply chains operated efficiently despite minor logistical challenges. Overall, the pricing environment remained stable, with levetiracetam prices aligning with input costs and sustained therapeutic demand across major European pharmaceutical markets.
This analysis can be extended to include detailed levetiracetam price information for a comprehensive list of countries.
Region | Countries Covered |
---|---|
Europe | Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries. |
Q2 2025:
In North America, levetiracetam prices remained steady, supported by stable demand from hospitals and outpatient neurology clinics. The region experienced consistent consumption across the U.S. and Canada, driven by its widespread use in seizure management. Minor pricing fluctuations were attributed to changes in production input costs and regulatory compliance expenses. Supply chains remained largely undisrupted, with generic manufacturers maintaining strong distribution networks. Overall, levetiracetam pricing reflected a balanced market, with rates closely aligned to manufacturing trends and consistent therapeutic demand throughout the quarter.
Specific levetiracetam historical data within the United States and Canada can also be provided.
Region | Countries Covered |
---|---|
North America | United States and Canada |
Q2 2025:
The report explores the levetiracetam trends and levetiracetam price chart in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.
In addition to region-wise data, information on levetiracetam prices for countries can also be provided.
Region | Countries Covered |
---|---|
Middle East & Africa | Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries. |
Q2 2025:
In the Asia Pacific region, levetiracetam prices remained largely stable during the second quarter of 2025, supported by consistent demand from neurological care segments and robust generic manufacturing across countries such as India and China. Moderate fluctuations were observed due to variable raw material and energy costs, as well as currency shifts impacting export margins. Regional pharmaceutical companies maintained steady production and supply, ensuring minimal disruptions to the market. Overall, the pricing environment reflected balanced supply-demand conditions, with levetiracetam prices aligning closely with input cost trends and sustained therapeutic use across major healthcare systems.
This levetiracetam price analysis can be expanded to include a comprehensive list of countries within the region.
Region | Countries Covered |
---|---|
Asia Pacific | China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries. |
Q2 2025:
Latin America's levetiracetam market is predominantly influenced by its rich natural reserves, particularly in countries like Chile and Brazil. However, political instability and inconsistent regulatory frameworks can lead to significant volatility in levetiracetam prices. Infrastructure challenges and logistical inefficiencies often impact the supply chain, affecting the region's ability to meet international demand consistently. Moreover, levetiracetam index, economic fluctuations, and currency devaluation are critical factors that need to be considered when analyzing levetiracetam pricing trends in this region.
This comprehensive review can be extended to include specific countries within the region.
Region | Countries Covered |
---|---|
Latin America | Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries. |
IMARC's latest publication, “Levetiracetam Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2025 Edition,” presents a detailed examination of the levetiracetam market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of levetiracetam at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents a detailed levetiracetam price trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting levetiracetam pricing, such as the dynamics of supply and demand, geopolitical influences, and sector-specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technological progress, facilitating informed strategic decision-making and forecasting.
The global levetiracetam market size reached US$ 1.59 Billion in 2024. By 2033, IMARC Group expects the market to reach US$ 3.55 Billion, at a projected CAGR of 9.13% during 2025-2033.
The report covers the latest developments, updates, and trends impacting the global levetiracetam industry, providing stakeholders with timely and relevant information. This segment covers a wide array of news items, including the inauguration of new production facilities, advancements in levetiracetam production technologies, strategic market expansions by key industry players, and significant mergers and acquisitions that impact the levetiracetam price trend.
Latest developments in the Levetiracetam industry:
Levetiracetam is an antiepileptic drug used to treat various types of seizures in individuals with epilepsy. It is commonly prescribed for partial-onset seizures, myoclonic seizures, and generalized tonic-colonic seizures in both adults and children. Levetiracetam works by modulating neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing brain electrical activity and reducing seizure frequency. It is available in multiple formulations, including oral tablets, extended-release tablets, oral solution, and intravenous injection, allowing for flexible administration based on patient needs.
Known for its favorable safety profile, levetiracetam is generally well-tolerated, with common side effects including dizziness, fatigue, and mood changes. It is often preferred for its minimal drug interactions and ease of dose adjustment. Due to its efficacy and tolerability, levetiracetam has become a widely used first-line therapy in seizure management and is frequently included in long-term epilepsy treatment plans.
Key Attributes | Details |
---|---|
Product Name | Levetiracetam |
Report Features | Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Levetiracetam Price Analysis, and Segment-Wise Assessment. |
Currency/Units | US$ (Data can also be provided in local currency) or Metric Tons |
Region/Countries Covered | The current coverage includes analysis at the global and regional levels only. Based on your requirements, we can also customize the report and provide specific information for the following countries: Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand* Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece* North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru* Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco* *The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client. |
Information Covered for Key Suppliers |
|
Customization Scope | The report can be customized as per the requirements of the customer |
Report Price and Purchase Option |
Plan A: Monthly Updates - Annual Subscription
Plan B: Quarterly Updates - Annual Subscription
Plan C: Biannually Updates - Annual Subscription
|
Post-Sale Analyst Support | 360-degree analyst support after report delivery |
Delivery Format | PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
IMARC offers trustworthy, data-centric insights into commodity pricing and evolving market trends, enabling businesses to make well-informed decisions in areas such as procurement, strategic planning, and investments. With in-depth knowledge spanning more than 1000 commodities and a vast global presence in over 150 countries, we provide tailored, actionable intelligence designed to meet the specific needs of diverse industries and markets.
1000
+Commodities
150
+Countries Covered
3000
+Clients
20
+Industry
IMARC delivers precise commodity pricing insights using proven methodologies and a wealth of data to support strategic decision-making.
Our extensive databases provide detailed commodity pricing, import-export trade statistics, and shipment-level tracking for comprehensive market analysis.
Through direct supplier surveys and expert interviews, we gather real-time market data to enhance pricing accuracy and trend forecasting.
We analyze industry reports, trade publications, and market studies to offer tailored intelligence and actionable commodity market insights.
Trusted by 3000+ industry leaders worldwide to drive data-backed decisions. From global manufacturers to government agencies, our clients rely on us for accurate pricing, deep market intelligence, and forward-looking insights.